Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- CANCER SCIENCE103(6) · pp.1099 · 2012
- 피인용
- Web of Science 49
- JCR IF
- JCR 2011 3.325
- ISSN
- 1347-9032
저자
- Komachi, Mayumi제1저자Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, JA
- Sato, KoichiGunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, JA
- Tobo, MasayukiGunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, JA
- Mogi, ChihiroGunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, JA
- Yamada, TakayukiGunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, JA
- Ohta, HideoKyowa Hakko Kirin Co Ltd, Dev Div, Dept Clin Sci, JA
- Tomura, HideakiGunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, JA
- Kimura, TakaoGunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, JA
- 임동순부산대학교, 약학대학, 약학부, KO
- Yanagida, KeisukeUniv Tokyo, Fac Med, JA
- Ishii, SatoshiAkita Univ, Grad Sch Med, Dept Immunol, JA
- Takeyoshi, IzumiGunma Univ, Grad Sch Med, Div Thorac & Visceral Organ Surg, JA
- Okajima, Fumikazu교신저자Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, JA
초록
Pancreatic cancer is highly metastatic and has a poor prognosis. However, there is no established treatment for pancreatic cancer. Lysophosphatidic acid (LPA) has been shown to be present in effluents of cancers and involved in migration and proliferation in a variety of cancer cells, including pancreatic cancer cells, in vitro. In the current study, we examined whether an orally active LPA antagonist is effective for pancreatic cancer tumorigenesis and metastasis in vivo. Oral administration of Ki16198, which is effective for LPA1 and LPA3, into YAPC-PD pancreatic cancer cell-inoculated nude mice significantly inhibited tumor weight and remarkably attenuated invasion and metastasis to lung, liver, and brain, in association with inhibition of matrix metalloproteinase (MMP) accumulation in ascites in vivo. Ki16198 inhibited LPA-induced migration and invasion in several pancreatic cancer cells in vitro, which was associated with the inhibition of LPA-induced MMP production. In conclusion, Ki16198 is a promising orally active LPA antagonist for inhibiting the invasion and metastasis of pancreatic cancer cells. The inhibitory effects of the antagonist on invasion and metastasis in vivo may be partially explained by the inhibition of motility activity and MMP production in cancer cells. (Cancer Sci 2012; 103: 10991104)
키워드
MALIGNANT ASCITESEDG-FAMILYCELLSMIGRATIONLPA(1)GROWTHLPA1STIMULATIONINHIBITIONMOTILITY
식별자
- WoS UID
- 000304758200018



로그인
연구물 목록으로